Company Description
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.
It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products.
The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands.
It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies.
The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013.
Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
| Country | Ireland |
| Founded | 1887 |
| IPO Date | Dec 16, 1991 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 9,140 |
| CEO | Patrick Lockwood-Taylor |
Contact Details
Address: The Sharp Building, Hogan Place Dublin, D02 TY74 Ireland | |
| Phone | 353 1 709 4000 |
| Website | perrigo.com |
Stock Details
| Ticker Symbol | PRGO |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001585364 |
| CUSIP Number | G97822103 |
| ISIN Number | IE00BGH1M568 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Patrick Lockwood-Taylor | President, Chief Executive Officer and Director |
| Eduardo Guarita Bezerra | Executive Vice President and Chief Financial Officer |
| Ronald C. Janish | Chief Transformation Officer and Executive Vice President of Global Operations and Supply Chain |
| Svend Andersen | Advisor |
| Kyle L. Hanson | Advisor |
| Shannon Hukill | Senior Director of Technical Operations |
| Alison Ives | Executive Vice President and Chief Scientific Officer |
| Bradley Joseph | Vice President of Global Investor Relations and Corporate Communications |
| Charles Atkinson | Executive Vice President, General Counsel and Secretary |
| Mary Reilly-Brest | Director of Global Organizational and Human Resource Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K/A | [Amend] Current report |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 31, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 10, 2024 | CERT | Certification by an exchange approving securities for listing |
| Oct 7, 2024 | 8-A12B | Registration of securities |
| Oct 2, 2024 | 25-NSE | Filing |
| Sep 17, 2024 | 8-K | Current Report |
| Sep 13, 2024 | 424B5 | Filing |
| Sep 13, 2024 | 144 | Filing |